Skip to main content
MedPathMedPath Home
Clinical Trials/NCT02089074
NCT02089074
Completed
Not Applicable

Systematic Follow up of Drug Treatment by Pharmacists in Secondary Prevention After Transient Ischemic Attack: Adherence and Cardiovascular Events in the First Three Months

Norwegian University of Science and Technology6 sites in 1 country265 target enrollmentNovember 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsIschemic Attack, TransientStroke

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Ischemic Attack, Transient
Sponsor
Norwegian University of Science and Technology
Enrollment
265
Locations
6
Primary Endpoint
adherence to drug treatment in secondary prevention after TIA
Status
Completed
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

Use of drugs is an important factor in secondary prophylaxis after transient ischemic attack (TIA), but studies show that adherence to the prescribed drugs is often poor. This randomised controlled trial aims to investigate whether a systematic follow up of drug treatment using medication reconciliation, medication reviews and patient counselling by clinical pharmacists, improves adherence and/or decreases cardiovascular events the first three months and the first year after TIA. Patient satisfaction will also be compared between the two groups.

Registry
clinicaltrials.gov
Start Date
November 2012
End Date
June 2016
Last Updated
9 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Probable or possible transient ischemic attack
  • •Residing in Central Norway
  • •Examined within 2 weeks after the onset of symptoms
  • •Modified Rankin Scale 3 or less and living at home
  • •enrolled in the MIDNOR-TIA study NCT02038725
  • •Informed consent

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

adherence to drug treatment in secondary prevention after TIA

Time Frame: 3 months

self reporting of adherence

Secondary Outcomes

  • adherence to drug treatment in secondary prevention after TIA(1 year)
  • Incidence of stroke and cardiovascular events and deaths(1 year)
  • patient satisfaction(1 year)
  • Persistence(1 year)
  • degree of disability or dependence in the daily activities(1 year)

Study Sites (6)

Loading locations...

Similar Trials

Completed
Not Applicable
Tailored Intervention to Improve Patient Adherence to Secondary Stroke Prevention MedicationStrokeTransient Ischemic Attack
NCT01684176Odense University Hospital211
Completed
Not Applicable
Cardiovascular and Torsades de Pointes Monitoring for PazopanibCarcinoma, Renal Cell
NCT01446224GlaxoSmithKline1
Unknown
Not Applicable
Impact of a Pluriprofessional Intervention to Improve Medication Adherence (Secondary Preventive Medication) in Patients After Ischemic StrokeIschemic Stroke
NCT02611440Hospices Civils de Lyon182
Completed
Not Applicable
The PREVENTS Trial: The Preventing Recurrent Events in Veterans Navigating Transient Ischemic Attack (TIA) or Stroke TrialStrokeTransient Ischemic Attack
NCT01020851Narrows Institute for Biomedical Research202
Completed
Not Applicable
Short Message Service (SMS) Reminders for Stroke Secondary Preventative MedicationsStrokeIschemic Attack, Transient
NCT02336412NHS Greater Glasgow and Clyde10